The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
The cover image is based on the Article The potential role of finerenone in patients with type 1 diabetes and chronic kidney disease by Maria Adelaida Escobar Vasco MD et al., https://doi.org/10.1111/dom.15773.
Aim
To compare the effectiveness of adding a glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) with adding basal insulin among adults with type 2 diabetes (T2D) and chronic kidney disease (CKD) already treated with a sodium‐glucose co‐transporter‐2 inhibitor (SGLT2i) and not reaching their glycaemic control targets.
Methods
A retrospective analysis of the Canadian LMC Diabetes Registry was conducted...
Aim
To assess the direct effect of intensive glycaemic control on periodontal tissues in patients with diabetes mellitus.
Materials and Methods
Twenty‐nine patients with type 2 diabetes were enrolled and hospitalized to receive a 2‐week intensive glycaemic control regimen. We observed and analysed the systemic and oral disease indicators before and after treatment and clarified the indicators related...